Information  X 
Enter a valid email address

EKF Diagnostics Hldg (EKF)

  Print      Mail a friend

Friday 08 March, 2019

EKF Diagnostics Hldg

Notice of Results

RNS Number : 2294S
EKF Diagnostics Holdings PLC
08 March 2019
 

 

EKF Diagnostics Holdings plc

("EKF", the "Company")

 

Notice of Results

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its preliminary results for the year ended 31 December 2018 on Wednesday 13 March 2019.

 

 

 

EKF Diagnostics Holdings plc 

www.ekfdiagnostics.com

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

 

Richard Evans, FD & COO

 

 

 

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

 

 

Walbrook PR Limited                                                                           Tel: 020 7933 8780 or [email protected] 

Paul McManus/ Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORFMGGFVNLGLZM

a d v e r t i s e m e n t